Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 10/20 | 0.65 |
| ▸ | GSK3B | P49841 | 10/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.43 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.43 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5829062 | 0.77 | GSK3B (1.00) | GSK3AGSK3BCDK1CDK2 | |
| SCHEMBL2055690 | 0.74 | GSK3A (0.64) | GSK3AGSK3BKCNH2CHRNA3 | |
| SCHEMBL2055677 | 0.74 | GSK3A (0.64) | GSK3AGSK3BKCNH2CHRNA3 | |
| SCHEMBL2055679 | 0.73 | GSK3A (0.65) | GSK3AGSK3BKCNH2CHRNA3 | |
| SCHEMBL2055737 | 0.67 | CHRNA3 (0.52) | GSK3AGSK3BKCNH2CHRNA3 | |
| SCHEMBL2055720 | 0.67 | KCNH2 (0.55) | GSK3AGSK3BKCNH2CHRNA3 | |
| SCHEMBL2055644 | 0.67 | CHRNA7 (0.62) | GSK3AGSK3BKCNH2DYRK1ACHRNA3 | |
| SCHEMBL628942 | 0.67 | EPHX2 (0.58) | GSK3AGSK3BCDK1CDK2CLK4 | |
| SCHEMBL1856200 | 0.66 | GSK3A (0.54) | GSK3AGSK3BKCNH2HDAC1HDAC2 | |
| SCHEMBL2055733 | 0.66 | GSK3A (0.53) | GSK3AGSK3BKCNH2CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105532-B2 | Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| US-20040077681-A1 | Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors | SMITHKLINE BEECHAM P.L.C (GB) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077681-A1 | Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors | GSK3B, GSK3A, GSKIP | GSK3A 2/4885GSK3B 1/4885KCNH2 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.